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Abstract 
A 30-year-old woman was diagnosed with a stage IA granulosa cell tumor (GCT) of the 
ovary in 1979. Following removal of the adnexal mass and complete surgical staging, she 
remained disease-free for 12 years. In 1991 she underwent a resection of a 
retroperitoneal mass, confirmed to be a recurrent GCT. Despite adjuvant radiation 
treatment at the time of recurrence, the patient presented five years later with 
abdominal pain, and was found to have a second recurrence. Over the next 10 years the 
patient had multiple recurrences and progressive disease despite surgical resection, 
cytotoxic, hormonal and targeted chemotherapy treatments. In conclusion, there is no 
standard management for recurrent GCT of the ovary. We review this patient’s treatment 
in the context of the current literature. 
 
Case Report 
A 30-year-old female was diagnosed with a granulosa cell tumor (GCT) of the right ovary in 1979 at 
the time of a right oophorectomy for an adnexal mass. The patient was then referred to the University of 
Texas M.D. Anderson Cancer Center and underwent a total abdominal hysterectomy, left 
salpingoophorectomy and staging procedure which revealed no residual disease. No further treatment 
was recommended. The patient remained disease-free for 12 years; however, in April 1991 she was 
noted to have a retroperitoneal mass. A second exploration was performed with removal of the mass, 
right lymphadenectomy and multiple biopsies. The mass was consistent with recurrent GCT; however, 
the lymph nodes and biopsies were negative. The patient was treated with pelvic radiation for a total 
dose of 5,000 cGy in 25 fractions and was without evidence of disease until June 1996, when the patient  
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underwent a second resection of a right retroperitoneal mass with a segmental resection of the right 
hemi-diaphragm for recurrent disease. Follow-up imaging studies were negative for disease. 
A year later, a recurrence of tumor was detected at the apex of the vagina and the patient was treated 
with leuprolide acetate 22.5 mg subcutaneously every three months and tamoxifen 20 mg orally twice 
daily. Several months later, however, progressive disease was noted and a fourth tumor-reductive 
surgery, lysis of adhesions, and small bowel resection with primary reanastomosis was performed. The 
patient again remained disease-free for four years until she developed a 14-cm right-sided liver mass. 
After a consultation with gastrointestinal surgical oncology, the patient underwent a partial right liver 
resection with removal of the mass in March 2002. 
One year later, recurrent tumor was noted in the right diaphragmatic area and the patient was 
treated with nine cycles of carboplatin and paclitaxel. She had a complete response to therapy; however, 
five months later, the patient was noted to have multiple peritoneal implants and lung nodules. The 
tumor was both estrogen (75%) and progesterone receptor positive (90%). She received megestrol 
acetate 40 mg orally four times daily for three months and was noted to have progressive disease. The 
patient was then treated with multiple chemotherapy regimens including bleomycin, etoposide, 
cisplatin (BEP) for six cycles, oral etoposide for two cycles, liposomal doxorubicin for nine cycles, 
gemcitabine for four cycles, and weekly topotecan for three cycles. Due to progressive disease, in 
September 2006 the patient was started on bevacizumab 7 mg/kg every other week and after three cycles 
was noted to have progression of disease. The patient was offered enrollment into a phase I clinical trial, 
however, she declined further treatment. 
Chemotherapy 
Platinum- and taxane-based chemotherapy have become the standard adjuvant 
treatment for gynecologic cancers, and it is often the first regimen used for GCT after 
surgical resection. Although data regarding the efficacy of carboplatin and paclitaxel in 
the treatment of GCT is lacking, multiple small studies have demonstrated tumor 
response to platinum-based regimens. 
Gershenson et al. [1] reported an overall response rate of 63% in 8 patients treated with 
cisplatin, doxorubicin, and cyclophosphamide, 38% complete response (CR) and 25% 
partial response (PR). Pectasides et al. [2] treated 10 patients, four with residual disease 
after primary diagnosis, and six with extensive disease at relapse. All of the patients 
treated after the primary diagnosis achieved a CR. In the six patients treated at the time of 
recurrence, one had a CR and one had a PR. Overall, toxicity was minimal. 
The combination of cisplatin, vinblastine and bleomycin – which has been used to 
treat testicular sex cord-stromal tumors – has also been described in treatment of GCT. 
Colombo et al. [3] treated 11 patients with this regimen, six had CRs and three PRs. In a 
prospective study, an overall response rate of 66% was found in seven patients with 
advanced or recurrent GCT [4]. This regimen was eventually changed to BEP, due to data 
in testicular sex cord-stromal tumors showing a similar response rate with less toxicity. 
In a prospective study at M.D. Anderson Cancer Center (MDACC) from 1988–1993, 
nine patient with sex cord-stromal tumors of the ovary were treated with first-line BEP. 
The overall response rate was 83%, 33% having a CR and 50% a PR. One of the five who 
initially responded to treatment (20%) had a durable response [5]. In a larger prospective 
study by the Gynecologic Oncology Group [6], 57 patients with stage II–IV sex cord-
stromal tumors (48 with GCT) received first-line BEP. Of those, 55 had a CR and 37% 
(14/38) had a negative second look. Sixty-nine percent of patients with advanced disease 
and 51% with recurrent disease remained disease-free at three years, thus making BEP an 
attractive first-line regimen for GCT.  
Case Rep Oncol 2010;3:14–18 
DOI: 10.1159/000274590 
Published online: January 13, 2010  © 2010 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
16
Hormonal Treatment of GCT 
Hormonal therapy is another promising option for treatment of GCT. In a review of 22 
GCT, all of the tumors were progesterone receptor positive, and 32% were estrogen 
receptor positive [7]. 
Progestins such as megestrol acetate reduce estrogen secretion by inhibiting the 
production of pituitary gonadotropin. It also interferes with the availability, stability and 
turnover of estrogen and may interact with genes at the estrogen or progestin receptor 
complex. One proposed mechanism of its anti-tumor effect is that continuous 
progesterone causes downregulation of progesterone receptors. 
Gonadotropin-releasing hormone (GnRH) analogs like leuprolide acetate inhibit 
gonadrotropin release through inhibition of ovarian steroidogenesis. This in turn may 
decrease stimulation of the granulosa cells. There have been several reported cases of 
response to GnRH analogs in recurrent GCT. Five patients with advanced ovarian GCT 
had stabilization of disease or decreased inhibin levels in the first three months of 
treatment with GnRH agonists [8]. A prospective study of leuprolide acetate therapy for 
six patients with recurrent or persistent GCT showed a 40% partial response rate, with 
stable disease in the remaining 60%. The progression-free interval was 3–13 months [9]. 
In all three of these studies, treatment with GnRH analogs was well tolerated and there 
were no significant side effects reported. 
Estrogen is also known to increase granulosa cell responsiveness to follicle stimulating 
hormone; therefore, estrogen suppression via hormonal manipulation may decrease cell 
proliferation in GCT. The use of aromatase inhibitors such as anastrozole in the 
treatment of refractory GCT has been recently reported. Two patients who had 
progressive disease despite multiple chemotherapy regimens as well as leuprolide acetate 
were found to respond to anastrozole for 14 and 18 months [10]. 
Radiotherapy in GCT 
Reports of radiation therapy for treatment of GCT of the ovary are generally favorable, 
although studies tend to be small and evaluation of disease response is not uniform. 
Fourteen patients with GCT and clinically measurable disease were treated with pelvic 
radiation at MDACC. A CR was reported in six patients (43%), three were without 
evidence of disease at 21 years follow-up, the other three patients recurred 4–5 years after 
completion of radiation. The remaining eight patients had either no response or 
progressed during radiation treatment. Median survival was 12 months [11]. A 50% CR 
rate with radiation treatment has also been reported in other studies [12]. 
Recently, Choan et al. [13] reported three cases of recurrent or residual GCT of the 
ovary treated with radiation, a dose of 30–50 gray. Tumor volume was reduced by 85–
90% in all three cases with duration of response of 5 to 21 months. Two of the three 
patients, however, developed recurrent disease within the abdomen but outside of the 
radiated field. 
Targeted Therapy and GCT 
Anti-angiogenic agents have been recently considered in treatment of multiple cancers 
including ovarian cancer. Metastasis through vascular spread is thought to be of  
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particular importance with ovarian cancer because of the absence of lymphatic channels 
in the ovary. Bevacizumab is a human monoclonal antibody that binds to vascular 
endothelial growth factor (VEGF). It has been used for treatment of colon, lung and 
breast cancer and is currently under investigation as a treatment for ovarian cancer. 
VEGF regulates angiogenesis in epithelial ovarian cancer which has been associated with 
disease progression; thus, bevacizumab is an attractive agent for ovarian cancer and 
possibly GCT. While the current data in ovarian cancer is somewhat limited, the efficacy 
of bevacizumab has been shown in several studies [14, 15]. Phase III trials of bevacizumab 
in heavily pre-treated ovarian cancer patients are currently underway. 
Conclusion 
GCT of the ovary are classified as stromal tumors and represent 2–5% of all ovarian 
cancers. In general, GCT are indolent tumors with late recurrence. Although this might 
be considered a favorable characteristic, their unpredictable behavior, particularly for the 
adult type, can complicate their management. This case report illustrates the 
characteristic behavior of a patient who developed multiple recurrences of GCT of the 
ovary. The literature is reviewed in the context of the treatment that this patient received. 
No standard adjuvant regimen has been defined to date, but there is data to support the 
use of platinum-based chemotherapy, as well as hormonal therapy. Radiation is also a 
therapeutic option for localized disease. The role of novel therapeutics will begin to 
unfold as further studies become available in both epithelial and stromal ovarian cancers. 
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